|
NL154600B
(nl)
|
1971-02-10 |
1977-09-15 |
Organon Nv |
Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
|
|
NL154598B
(nl)
|
1970-11-10 |
1977-09-15 |
Organon Nv |
Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
|
|
NL154599B
(nl)
|
1970-12-28 |
1977-09-15 |
Organon Nv |
Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
|
|
US3901654A
(en)
|
1971-06-21 |
1975-08-26 |
Biological Developments |
Receptor assays of biologically active compounds employing biologically specific receptors
|
|
US3853987A
(en)
|
1971-09-01 |
1974-12-10 |
W Dreyer |
Immunological reagent and radioimmuno assay
|
|
US3867517A
(en)
|
1971-12-21 |
1975-02-18 |
Abbott Lab |
Direct radioimmunoassay for antigens and their antibodies
|
|
NL171930C
(nl)
|
1972-05-11 |
1983-06-01 |
Akzo Nv |
Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
|
|
US3850578A
(en)
|
1973-03-12 |
1974-11-26 |
H Mcconnell |
Process for assaying for biologically active molecules
|
|
US3935074A
(en)
|
1973-12-17 |
1976-01-27 |
Syva Company |
Antibody steric hindrance immunoassay with two antibodies
|
|
US3996345A
(en)
|
1974-08-12 |
1976-12-07 |
Syva Company |
Fluorescence quenching with immunological pairs in immunoassays
|
|
US4034074A
(en)
|
1974-09-19 |
1977-07-05 |
The Board Of Trustees Of Leland Stanford Junior University |
Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
|
|
US3984533A
(en)
|
1975-11-13 |
1976-10-05 |
General Electric Company |
Electrophoretic method of detecting antigen-antibody reaction
|
|
US4098876A
(en)
|
1976-10-26 |
1978-07-04 |
Corning Glass Works |
Reverse sandwich immunoassay
|
|
US4879219A
(en)
|
1980-09-19 |
1989-11-07 |
General Hospital Corporation |
Immunoassay utilizing monoclonal high affinity IgM antibodies
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5011771A
(en)
|
1984-04-12 |
1991-04-30 |
The General Hospital Corporation |
Multiepitopic immunometric assay
|
|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
|
CA2006008C
(en)
|
1988-12-20 |
2000-02-15 |
Donald J. Kessler |
Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
|
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
|
ATE300615T1
(de)
|
1990-08-29 |
2005-08-15 |
Genpharm Int |
Transgene mäuse fähig zur produktion heterologer antikörper
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US6933286B2
(en)
|
1991-03-19 |
2005-08-23 |
R. Martin Emanuele |
Therapeutic delivery compositions and methods of use thereof
|
|
US20020123476A1
(en)
|
1991-03-19 |
2002-09-05 |
Emanuele R. Martin |
Therapeutic delivery compositions and methods of use thereof
|
|
US6235887B1
(en)
|
1991-11-26 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
|
|
US5281521A
(en)
|
1992-07-20 |
1994-01-25 |
The Trustees Of The University Of Pennsylvania |
Modified avidin-biotin technique
|
|
US5721138A
(en)
|
1992-12-15 |
1998-02-24 |
Sandford University |
Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
|
|
US5599703A
(en)
|
1993-10-28 |
1997-02-04 |
The United States Of America As Represented By The Secretary Of The Navy |
In vitro amplification/expansion of CD34+ stem and progenitor cells
|
|
US5807718A
(en)
|
1994-12-02 |
1998-09-15 |
The Scripps Research Institute |
Enzymatic DNA molecules
|
|
CA2245224A1
(en)
|
1998-08-14 |
2000-02-14 |
Jiang-Hong Giong |
Chemokine receptor antagonists and chemotherapeutics
|
|
CA2305787A1
(en)
|
2000-05-09 |
2001-11-09 |
The University Of British Columbia |
Cxcr4 antagonist treatment of hematopoietic cells
|
|
WO2000009152A1
(en)
|
1998-08-14 |
2000-02-24 |
The University Of British Columbia |
Therapeutic chemokine receptor antagonists
|
|
WO1999047158A2
(en)
|
1998-03-13 |
1999-09-23 |
The University Of British Columbia |
Therapeutic chemokine receptor antagonists
|
|
CA2328457A1
(en)
|
1998-06-20 |
1999-12-29 |
Washington University |
Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
|
|
US6512102B1
(en)
*
|
1998-12-31 |
2003-01-28 |
Chiron Corporation |
Compositions and methods of diagnosis and treatment using casein kinase I
|
|
GB2375172A
(en)
*
|
2000-02-07 |
2002-11-06 |
Quark Biotech Inc |
Fas pathway genes
|
|
DE60103052T2
(de)
|
2000-05-09 |
2005-03-03 |
The University Of British Columbia, Vancouver |
Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
|
|
JP4808363B2
(ja)
|
2000-09-05 |
2011-11-02 |
バイオカイン セラピューティックス リミテッド |
新規ポリペプチド及びこれを含む抗ｈｉｖ剤
|
|
EP1390497A2
(en)
|
2001-05-25 |
2004-02-25 |
Genset |
Human cdnas and proteins and uses thereof
|
|
US20050171005A1
(en)
*
|
2002-04-29 |
2005-08-04 |
Yinon Ben-Neriah |
Methods and compositions for modulating beta-catenin phosphorylation
|
|
WO2004020462A1
(ja)
|
2002-08-27 |
2004-03-11 |
Fujii, Nobutaka |
Ｃｘｃｒ４拮抗薬およびその用途
|
|
DE10240064A1
(de)
|
2002-08-30 |
2004-03-11 |
Universitätsklinikum Freiburg |
CXCR4-Rezeptor-Antagonisten
|
|
US20050002939A1
(en)
|
2002-12-23 |
2005-01-06 |
Albert Zlotnik |
Tumor killing/tumor regression using CXCR4 antagonists
|
|
JP2006524242A
(ja)
|
2003-03-27 |
2006-10-26 |
エモリー ユニバーシティー |
Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法
|
|
EP1613613B1
(en)
|
2003-04-11 |
2021-06-02 |
Genzyme Corporation |
Cxcr4 chemokine receptor binding compounds
|
|
JP4970948B2
(ja)
|
2003-12-05 |
2012-07-11 |
ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ |
癌幹細胞の同定、単離、および除去の方法
|
|
EP2298291A3
(en)
|
2004-06-18 |
2011-08-03 |
Agennix USA Inc. |
Kinase inhibitors for treating cancers
|
|
TW200628156A
(en)
*
|
2004-11-04 |
2006-08-16 |
Bristol Myers Squibb Co |
Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
|
|
EP2152879B1
(en)
|
2007-05-01 |
2012-11-14 |
Santaris Pharma A/S |
Rna antagonist compounds for the modulation of beta-catenin
|
|
FR2918061B1
(fr)
*
|
2007-06-28 |
2010-10-22 |
Sanofi Aventis |
Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
|
|
US9623109B2
(en)
*
|
2008-05-27 |
2017-04-18 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods of killing cells and use of same in prevention and treatment of cancer
|
|
CZ2012538A3
(cs)
*
|
2012-08-08 |
2014-02-19 |
Masarykova Univerzita |
Inhibitory pro léčbu B-buněčné chronické lymfocytární leukémie
|